Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.
about
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsPrognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung CancerMolecular Testing of Lung CancersPrognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCRCorrelation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcomaSetting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps.Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications.Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung CancerFGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal CarcinomaIsolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method.Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis.Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma.Targeted therapy for squamous cell lung cancer.EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy.Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomasGenetic alteration profiling of patients with resected squamous cell lung carcinomas.Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma.Fibroblast Growth Factor Receptor 1 (FGFR1), Partly Related to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Microvessel Density, is an Independent Prognostic Factor for Non-Small Cell Lung CancerFibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.MDM2 and CDK4 amplifications are rare events in salivary duct carcinomasReceptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung.Prognostic and predictive biomarkers in lung cancer. A review.Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung.Targeting FGFR in Squamous Cell Carcinoma of the Lung.Activated cdc42-associated kinase is up-regulated in non-small-cell lung cancer and necessary for FGFR-mediated AKT activation.A genomics-based classification of human lung tumors.MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.Complexity of FGFR signalling in metastatic urothelial cancer.Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?
P2860
Q26998790-AC7FD577-6CA9-4CFD-9172-1FF02CCE1092Q27853061-A2E407AB-5486-4661-AB5A-34D225038FE2Q28077032-224A97C1-1D4B-41E1-A787-4E269DCA4EDDQ33729715-30997171-B78E-4E4A-A945-94663E78179BQ33750128-C5A9BADE-6652-45B7-AD2E-2F9114CB25FEQ35000497-9468D44D-F9A6-4BA1-8B15-486A5A881834Q35047444-DD7D1A90-4705-432F-8B56-D83B94A2A070Q35065555-A647E499-90E8-4EE8-B4D9-C277BD1E2BE4Q35084915-02637F5F-9F26-41A0-91B5-DE36C34A7231Q35149263-8553E421-6FEA-4D78-9FBC-B3A73500F453Q35176080-E643D7E7-F789-4965-AE19-02DED96E5ED7Q35206634-BA7E7499-27C4-4BD3-8FDF-E7C71EDF1607Q35273802-5E6A7F40-4F48-4DE4-A6A6-556518F06977Q35743009-8EEB1FEF-721F-4C63-A51C-B6B61022043DQ35837391-D51B37E0-F205-4AF6-8988-6D16FF357D28Q35842078-D1EAB234-1F64-4BCF-AFCD-9B37B02DCAF5Q36228558-F76ADB7A-1615-433E-8E2A-1AE26333BD9EQ36450685-DF5D6B6D-73D9-4B90-A85C-DCE358BE8410Q36528389-A67DAADA-E42D-4BEC-91F3-4A3F6F0B9390Q37096910-D05E28EA-A918-4A7B-821A-35F180DAB8C9Q37204247-77D406C0-818C-473D-ACE9-F2430C03002DQ37225394-A4531DAF-AF25-466B-8495-E0437FC6528EQ37392781-A45FBCF2-A0E8-497F-862C-FFCBD3ABB75CQ37444264-CA84A6E3-EDB9-4EB1-84C2-D8EB9C08807AQ37603125-E2BD71E2-4384-4745-80CF-858378BA945CQ37687627-8BB93768-EC5F-4A00-AEEE-80C04DC95324Q37688930-1AE73138-86B5-438E-AC85-87CC3237BE74Q38130137-056B470C-1398-46A6-8C61-2EC92F44CB21Q38178187-E16FF88C-BA2D-4F28-8A70-E579DAF59BB5Q38390024-BBB02EDD-703F-468A-B835-9397A9AFDC35Q38690050-C7180669-0CA0-413A-849E-FAD1A5BD0781Q38878596-2757658A-0190-48C1-8165-0AED23681DE0Q39123357-17F8CCED-A613-46E8-93B9-8AC7A0945963Q39286355-4A18E97A-17F8-4019-9B9F-85C53811F2E1Q40343596-9632DAE3-4EE1-4923-AA24-4AA914997497Q40396999-0FA1FF9E-2DBB-435F-AA87-0791F6D50A71Q40770256-BD2E990E-E791-4EFF-8CF5-E142EAF96357Q47141006-25B94795-BC61-45A2-9C1E-CC121A80146EQ47141559-EBFA4883-CF47-4678-868D-98EDE26A2898Q47164059-892C0C85-6206-4CFD-A0FF-18B843A5B136
P2860
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Definition of a fluorescence i ...... in squamous cell lung cancer.
@en
Definition of a fluorescence i ...... in squamous cell lung cancer.
@nl
type
label
Definition of a fluorescence i ...... in squamous cell lung cancer.
@en
Definition of a fluorescence i ...... in squamous cell lung cancer.
@nl
prefLabel
Definition of a fluorescence i ...... in squamous cell lung cancer.
@en
Definition of a fluorescence i ...... in squamous cell lung cancer.
@nl
P2093
P2860
P1433
P1476
Definition of a fluorescence i ...... s in squamous cell lung cancer
@en
P2093
Andreas Schlesinger
Christian Mattonet
Elke Binot
Ellen Paggen
Erich Stoelben
Friederike Göke
Hans-Ulrich Schildhaus
Jürgen Wolf
Katja Schmitz
Kerstin Albus
P2860
P2888
P304
P356
10.1038/MODPATHOL.2012.102
P577
2012-06-08T00:00:00Z
P5875
P6179
1046670140